DURHAM, NC--(Marketwired - January 16, 2014) -
Patheon Inc., a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, will showcase its late-stage API development capabilities at InformEx in Miami, Fla., January 21-24, 2014.
Patheon's Kevin Kane, Ph.D., account executive, will present, "Moving your API Beyond Phase I Clinical Studies: Formulation Development Challenges and Case Studies" on Thursday, Jan. 23 at 3 p.m. This presentation will survey some of the challenges encountered in case studies on formulation development and the manufacture of clinical trial material for Phase II and III studies. InformEx will be hosting open floor presentations at this year's conferences, so attendees will receive a headset to listen to presentations as they roam the floor.
In addition, many Patheon executives as well as technical and scientific experts will also attend InformEx and will be available to discuss Patheon's API development capabilities. Patheon's experience encompasses thousands of projects for pharmaceutical and biotechnology companies of all types and sizes. The company gives access to the expertise, proven quality and global resources to bring drug candidates from preclinical stages through commercial production. Patheon will be exhibiting at Booth #1010 for the duration of the conference. To schedule a meeting in advance, please email firstname.lastname@example.org.
InformEx is the only event of its kind offering participants a direct view of what is happening globally across the fine, specialty and custom chemical marketplace. The event brings together an international mix of motivated buyers and sellers of high value chemistry for four days of sourcing, education and networking.
For more information on upcoming events, visit http://www.patheon.com/Knowledge-Library/Events.aspx.
Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Through the company's recent acquisition of Banner Pharmacaps -- a market leader in soft gelatin capsule technology -- Patheon now also includes a proprietary products and technology business.
Patheon provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. The company's integrated network consists of 15 locations, including 12 commercial contract manufacturing facilities and 9 development centers across North America and Europe. Patheon enables customer products to be launched with confidence anywhere in the world. For more information, visit www.patheon.com.